Cardialen announced today that it received FDA investigational device exemption (IDE) approval for its MultiPulse therapy platform. Minneapolis-based Cardialen designed its MultiPulse therapy (MPT) to treat paroxysmal and persistent AFib through a sequence of low-energy electrical pulses that restore abnormally rapid heart rates to a normal rhythm. The low-energy method of electrical pulse delivery provides […]
Investments in Medical Alley medtech companies, which had dipped in recent years, have made a comeback, according to the Minnesota trade association. Device companies raised $90 million in the third quarter, pushing the year-to-date total to nearly $200 million raised by 33 companies. Q3’s largest raises in medtech included Urotronic ($26 million, including $20M in Series B funds), 4C Medical ($17 million), […]
Cardialen said today that it closed a $17 million Series B round for the low-energy defibrillation technology it’s developing. The Minneapolis-based company said RiverVest Venture partners led the round, joined by Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The proceeds are earmarked for further clinical work on Cardialen’s “unpinning termination” therapy, which is designed to […]
Cardialen is closing in on a $4 million equity round, after raising $2.5 million from 18 unnamed investors.
Minneapolis and St. Louis-based Cardialen is developing a low-energy implant for atrial fibrillation designed to control the fibrillation without damaging heart tissue, according to its website.
The technology uses series of lower-energy pulses rather than a single high-energy shock to effect the therapy, according to the website.